Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs

Drug Discovery Today

Volumn 20, Issue 8, 2015, Pages 958-968

  Rajasekaran, Rajalakshmi ^a   Chen, Yi Ping Phoebe ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; CYSTEINE PROTEINASE; PROTEIN KINASE; PROTEIN N MYRISTOYLTRANSFERASE; ANTITRYPANOSOMAL AGENT;

ARTICLE; DRUG DESIGN; FOLATE METABOLISM; GLYCOLYSIS; HUMAN; LEISHMANIA; LEISHMANIASIS; MOLECULAR DYNAMICS; NONHUMAN; STRUCTURAL GENOMICS; TRYPANOSOMA; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GENOME; GENOMICS; GENOTYPE; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; PARASITOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE; GENOME, PROTOZOAN; GENOMICS; GENOTYPE; HUMANS; LEISHMANIA; LEISHMANIASIS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS;

EID: 84940766466     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.04.006     Document Type: Review

References (84)

1. A.J. Davis, and et al. Drugs against leishmaniasis: a synergy of technology and partnerships Trends Parasitol. 20 2004 73 76
2. E. Chatelain, and J.R. Ioset Drug discovery and development for neglected diseases: the DNDi model Drug Des. Dev. Ther. 5 2011 175 181
3. L.H. Freitas-Junior, and et al. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int. J. Parasitol. Drugs Drug Resist. 2 2012 11 19
4. S. Sundar Drug resistance in Indian visceral leishmaniasis Trop. Med. Int. Health 6 2001 849 854
5. S.L. Croft, and G.H. Coombs Leishmaniasis current chemotherapy and recent advances in the search for novel drugs Trends Parasitol. 19 2003 502 508
6. T.P.C. Dorlo, and et al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure J. Infect. Dis. 210 2014 146 153
7. J. van Griensven, and et al. Combination therapy for visceral leishmaniasis Lancet Infect. Dis. 10 2010 184 194
8. S. Sundar, and et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial Lancet 377 2011 477 486
9. K. Jain, and N.K. Jain Novel therapeutic strategies for treatment of visceral leishmaniasis Drug Discov. Today 18 2013 1272 1281
10. R. Garcia-Hernandez, and et al. Leishmania donovani develops resistance to drug combinations PLoS Negl. Trop. Dis. 6 2012 e1974
11. R.M. Reguera, and et al. Target-based vs. phenotypic screenings in Leishmania drug discovery: a marriage of convenience or a dialogue of the deaf? Int. J. Parasitol. Drugs Drug Resist. 4 2014 355 357
12. I.H. Gilbert Drug discovery for neglected diseases: molecular target-based and phenotypic approaches J. Med. Chem. 56 2013 7719 7726
13. R. Don, and J.-R. Ioset Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections Parasitology 141 2014 140 146
14. E. Chatelain, and J.-R. Ioset Drug discovery and development for neglected diseases: the DNDi model Drug Des. Dev. Ther. 5 2011 175 181
15. M.A. Lindsay Target discovery Nat. Rev. Drug Discov. 2 2003 831 838
16. S.P. Butcher Target discovery and validation in the post-genomic era Neurochem. Res. 28 2003 367 371
17. A.C. Ivens, and et al. The genome of the kinetoplastid parasite Leishmania major Science 309 2005 436 442
18. C. Cantacessi, and et al. The past, present, and future of Leishmania genomics and transcriptomics Trends Parasitol. 31 2015 100 108
19. R.A. Scheltema, and et al. The potential of metabolomics for Leishmania research in the post-genomics era Parasitology 137 2010 1291 1302
20. I.M. Vincent, and et al. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei PLoS Negl. Trop. Dis. 6 2012 e1618
21. R. Pink, and et al. Opportunities and challenges in antiparasitic drug discovery Nat. Rev. Drug Discov. 4 2005 727 740
22. S.C. Roberts The genetic toolbox for Leishmania parasites Bioeng. Bugs 2 2011 320 326
23. R.G. Walker, and et al. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase PLoS Negl. Trop. Dis. 5 2011 e1033
24. F. Aguero, and et al. Genomic-scale prioritization of drug targets: the TDR Targets database Nat. Rev. Drug Discov. 7 2008 900 907
25. G.J. Crowther, and et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach PLoS Negl. Trop. Dis. 4 2010 e804
26. P. Bhargava, and R. Singh Developments in diagnosis and antileishmanial drugs Interdiscip. Perspect. Infect. Dis. 2012 2012 13
27. M. Sharma, and P.M.S. Chauhan Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges Fut. Med. Chem. 4 2012 1335 1365
28. R. Rajasekaran, and Y-P.P. Chen Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads J. Mol. Model. 18 2012 4089 4100
29. S. Khabnadideh, and et al. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase Bioorg. Med. Chem. 13 2005 2637 2649
30. T.J. Vickers, and S.M. Beverley Folate metabolic pathways in Leishmania Essays Biochem. 51 2011 63 80
31. S. Ferrari, and et al. Targeting the trypanosomatidic enzymes pteridine reductase and dihydrofolate reductase T. Jäger, Trypanosomatid Diseases: Molecular Routes to Drug Discovery 2013 Wiley-VCH Verlag GmbH & Co 445 472
32. P. Das, and et al. Protease inhibitors in potential drug development for leishmaniasis Ind. J. Biochem. Biophys. 50 2013 363 376
33. N. Lee, and et al. Characterization of metacaspases with trypsin-like activity and their putative role in programmed cell death in the protozoan parasite Leishmania Eukaryotic Cell 6 2007 1745 1757
34. P. Raina, and S. Kaur Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani Mol. Cell. Biochem. 359 2012 135 149
35. E. Castanys-Muñoz, and et al. Leishmania mexicana metacaspase is a negative regulator of amastigote proliferation in mammalian cells Cell Death Dis. 3 2012 e385
36. B. Meslin, and et al. Are protozoan metacaspases potential parasite killers? Parasit. Vectors 4 2011 26
37. J. Golenser, and et al. Probing for antiparasitic drugs Mini-Rev. Med. Chem. 6 2006 121 122
38. E.C. Saunders, and et al. Induction of a stringent metabolic response in intracellular stages of Leishmania mexicana leads to increased dependence on mitochondrial metabolism PLoS Pathog. 10 2014 e1003888
39. T. Naderer, and et al. Evidence that intracellular stages of Leishmania major utilize amino sugars as a major carbon source PLoS Pathog. 6 2010 e1001245
40. N.B.H. Lozano, and et al. Identification of electronic and structural descriptors of adenosine analogues related to inhibition of leishmanial glyceraldehyde-3-phosphate dehydrogenase Molecules 18 2013 5032 5050
41. R. Gupta, and et al. Characterization of glycolytic enzymes rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis PLoS ONE 9 2014 e86073
42. J. Maldonado, and et al. A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice Exp. Mol. Pathol. 80 2006 289 294
43. S. Chandra, and et al. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery Expert Opin. Ther. Targets 14 2010 739 757
44. M. Berg, and et al. Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy? Curr. Med. Chem. 17 2010 2456 2481
45. A.K. Datta, and et al. Antiparasitic chemotherapy: tinkering with the purine salvage pathway Adv. Exp. Med. Biol. 625 2008 116 132
46. J.M. Boitz, and et al. Purine salvage in Leishmania: complex or simple by design? Trends Parasitol. 28 2012 345 352
47. S.M. da Silva, and et al. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis Antimicrob. Agents Chemother. 56 2012 2858 2867
48. N.S. Carter, and et al. Purine and pyrimidine metabolism in Leishmania Adv. Exp. Med. Biol. 625 2008 141 154
49. D. Nico, and et al. Leishmania donovani nucleoside hydrolase terminal domains in cross-protective immunotherapy against Leishmania amazonensis murine infection Front. Immunol. 5 2014 273
50. D. Nico, and et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response PLoS Negl. Trop. Dis. 4 2010 e866
51. K.M. Grant, and et al. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity Antimicrob. Agents Chemother. 48 2004 3033 3042
52. D. Smirlis, and et al. Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death Parasit. Vectors 3 2010 107
53. E. Xingi, and et al. 6-Br-5-methylindirubin-3′oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis Int. J. Parasit. 39 2009 1289 1303
54. K.K. Ojo, and et al. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3 Mol. Biochem. Parasitol. 176 2011 98 108
55. C. Naula, and et al. Protein kinases as drug targets in trypanosomes and Leishmania Biochim. Biophys. Acta 30 2005 1 2
56. P. Saudagar, and V.K. Dubey Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani Biol. Chem. 392 2011 1113 1122
57. H.P. Price, and et al. Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites J. Biol. Chem. 278 2003 7206 7214
58. J.A. Brannigan, and et al. N-Myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis J. Mol. Biol. 396 2010 985 999
59. E.W. Tate, and et al. N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis Parasitology 141 2014 37 49
60. A.S. Bell, and et al. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs PLoS Negl. Trop. Dis. 6 2012 e1625
61. J.J. Barker Antibacterial drug discovery and structure-based design Drug Discov. Today 11 2006 391 404
62. E. Fan, and et al. Structural genomics of pathogenic protozoa: an overview Struct. Proteomics 426 2008 497 513
63. C.L.M.J. Verlinde, and et al. Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium Curr. Top. Med. Chem. 9 2009 1678 1687
64. W.F. Anderson Structural genomics and drug discovery for infectious diseases Infect. Disord. Drug Targets 9 2009 507 517
65. J.P. Hughes, and et al. Principles of early drug discovery Br. J. Pharmacol. 162 2011 1239 1249
66. S. Kalyaanamoorthy, and Y-P.P. Chen Structure-based drug design to augment hit discovery Drug Discov. Today 16 2011 831 839
67. P.V. Desai, and et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database J. Med. Chem. 47 2004 6609 6615
68. S. Suresh, and et al. Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors J. Mol. Biol. 309 2001 423 435
69. S. Kalyaanamoorthy, and Y-P.P. Chen Modelling and enhanced molecular dynamics to steer structure-based drug discovery Progr. Biophys. Mol. Biol. 114 2014 123 136
70. S. Kalyaanamoorthy, and Y-P.P. Chen Exploring inhibitor release pathways in histone deacetylases using random acceleration molecular dynamics simulations J. Chem. Inf. Model. 52 2012 589 603
71. A. Grover, and et al. A leishmaniasis study: structure-based screening and molecular dynamics mechanistic analysis for discovering potent inhibitors of spermidine synthase Biochim. Biophys. Acta Proteins Proteomics 1824 2012 1476 1483
72. A. Merlino, and et al. Homology modeling of T. cruzi and L. major NADH-dependent fumarate reductases: ligand docking, molecular dynamics validation, and insights on their binding modes J. Mol. Graph. Model. 48 2014 47 59
73. T.T. Ashburn, and K.B. Thor Drug repositioning: Identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683
74. B. Readhead, and J. Dudley Translational bioinformatics approaches to drug development Adv. Wound Care 2 2013 470 489
75. J.T. Dudley, and et al. Exploiting drug-disease relationships for computational drug repositioning Brief. Bioinform. 12 2011 303 311
76. T.P.C. Dorlo, and et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis J. Antimicrob. Chemother. 67 2012 2576 2597
77. A.K. Haldar, and et al. Use of antimony in the treatment of leishmaniasis: current status and future directions Mol. Biol. Int. 2011 2011 23
78. M.J. Corral, and et al. In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum Antimicrob. Agents Chemother. 58 2014 1596 1602
79. S. Sundar, and J. Chakravarty Liposomal amphotericin B and leishmaniasis: dose and response J. Global Infect. Dis. 2 2010 159 166
80. S. Sundar, and et al. Injectable paromomycin for visceral leishmaniasis in India N. Engl. J. Med. 356 2007 2571 2581
81. M.T. Harris, and et al. Targeting protozoan parasite metabolism: glycolytic enzymes in the therapeutic crosshairs Curr. Med. Chem. 21 2014 1668 1678
82. N. Sharma, and et al. Evaluation of plumbagin and its derivative as potential modulators of redox thiol metabolism of Leishmania parasite Parasitol. Res. 110 2012 341 348
83. Y.T. Chen, and et al. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors Bioorg. Med. Chem. Lett. 18 2008 5860 5863
84. I.H. Gilbert Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes Biochim. Biophys. Acta 1587 2002 249 257